Nordic Pharma's Lacrifill Canalicular Gel Introduced in Major Dry Eye Report
Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has made significant strides in the treatment of dry eye syndrome with its newly introduced LACRIFILL® Canalicular Gel. This innovative therapy has recently gained recognition by being included in the latest report of the Dry Eye Workshop (DEWS) III, produced by the Tear Film and Ocular Surface Society (TFOS) and published in the American Journal of Ophthalmology. This development marks a notable milestone in ocular health and emphasizes Nordic Pharma's commitment to advancing eye care solutions.
The comprehensive DEWS III report, which appeared in the June 2025 issue of the journal, highlights recent advancements in dry eye management and therapy. Within this document, in Section 6.2.4, entitled "Newer Plug Designs and Other Technologies," two pivotal studies regarding the Lacrifill Canalicular Gel were cited. According to the first study, results demonstrated statistically significant improvements in corneal staining and other clinical measurements occurring three months after the administration of the gel.
Further validating these findings, the second study compared LACRIFILL Canalicular Gel with a standard hydrogel punctal plug, concluding that the new cross-linked hyaluronic acid (HA) filler displayed not only safety and good tolerability, but also sustained significant improvements in dry eye symptoms over a six-month observation period.
To further share insights on the efficacy of LACRIFILL, the results of an ongoing study titled "Evaluation of Lacrimal Punctal Plug Insertion for Dry Eye Relief in Ophthalmology Clinic Patients Using Self-Reported Improvement and OSDI Questionnaires" were presented at the Women in Ophthalmology (WIO) Summer Symposium held from August 7 to August 10. In this study involving 117 patients, a remarkable 66.25% reported at least a 50% improvement in their symptoms one month post-insertion of the Lacrifill gel, with a considerable number indicating a 90-100% improvement, particularly in symptoms such as burning and the sensation of sand in the eyes.
Dr. Monica Patel, who spearheaded this study, noted that the results corroborate the efficacy of Lacrifill Canalicular Gel across various patient demographics, including those with comorbid conditions like diabetes and glaucoma. The positive outcomes observed not only highlight the gel's therapeutic potential but also endorse self-reported assessments as a legitimate measure of treatment effectiveness.
In addition to the symposium presentations, two recently published case studies underscore the clinical benefits of LACRIFILL Canalicular Gel. One presented in Cataract and Refractive Surgery Today illustrated a patient's symptom relief post-refractive cataract surgery after unsuccessful attempts to alleviate blurry vision with traditional treatments, which included steroid drops and artificial tears. The administration of Lacrifill helped stabilize the tear film, leading to noticeable improvements in visual clarity and overall eye health.
Another case study in Modern Optometry dealt with a patient afflicted by Demodex blepharitis and unmanageable dry eye disease. Following treatment with Lacrifill, this individual achieved significant improvements in the Ocular Surface Disease Index (OSDI) scores and notable clearance of corneal findings.
The ongoing and emerging research surrounding LACRIFILL establishes it as a promising option for those suffering from dry eyes, a condition that affects millions worldwide. Nordic Pharma remains dedicated to expanding its portfolio and offering advanced therapeutic solutions. As the company progresses with its acquisitions and strategic development, it aims to enhance its foothold in the fields of ophthalmology, rheumatology, and women's health, leveraging its unique position within the global biopharmaceutical landscape. The company invites healthcare providers and patients to explore further details and ordering options for LACRIFILL Canalicular Gel via their website at lacrifill.com.
For further inquiries, Nordic Pharma can be contacted via Kate Popova, Project and Contract Manager, or Gail Feerrar, Director of Sales and Marketing, whose contact information is available in the press release. Nordic Pharma's commitment to enhancing patient care and driving innovation in eye health signifies a progressive pathway for addressing the challenges posed by dry eye syndrome and related ocular conditions.
The comprehensive DEWS III report, which appeared in the June 2025 issue of the journal, highlights recent advancements in dry eye management and therapy. Within this document, in Section 6.2.4, entitled "Newer Plug Designs and Other Technologies," two pivotal studies regarding the Lacrifill Canalicular Gel were cited. According to the first study, results demonstrated statistically significant improvements in corneal staining and other clinical measurements occurring three months after the administration of the gel.
Further validating these findings, the second study compared LACRIFILL Canalicular Gel with a standard hydrogel punctal plug, concluding that the new cross-linked hyaluronic acid (HA) filler displayed not only safety and good tolerability, but also sustained significant improvements in dry eye symptoms over a six-month observation period.
To further share insights on the efficacy of LACRIFILL, the results of an ongoing study titled "Evaluation of Lacrimal Punctal Plug Insertion for Dry Eye Relief in Ophthalmology Clinic Patients Using Self-Reported Improvement and OSDI Questionnaires" were presented at the Women in Ophthalmology (WIO) Summer Symposium held from August 7 to August 10. In this study involving 117 patients, a remarkable 66.25% reported at least a 50% improvement in their symptoms one month post-insertion of the Lacrifill gel, with a considerable number indicating a 90-100% improvement, particularly in symptoms such as burning and the sensation of sand in the eyes.
Dr. Monica Patel, who spearheaded this study, noted that the results corroborate the efficacy of Lacrifill Canalicular Gel across various patient demographics, including those with comorbid conditions like diabetes and glaucoma. The positive outcomes observed not only highlight the gel's therapeutic potential but also endorse self-reported assessments as a legitimate measure of treatment effectiveness.
In addition to the symposium presentations, two recently published case studies underscore the clinical benefits of LACRIFILL Canalicular Gel. One presented in Cataract and Refractive Surgery Today illustrated a patient's symptom relief post-refractive cataract surgery after unsuccessful attempts to alleviate blurry vision with traditional treatments, which included steroid drops and artificial tears. The administration of Lacrifill helped stabilize the tear film, leading to noticeable improvements in visual clarity and overall eye health.
Another case study in Modern Optometry dealt with a patient afflicted by Demodex blepharitis and unmanageable dry eye disease. Following treatment with Lacrifill, this individual achieved significant improvements in the Ocular Surface Disease Index (OSDI) scores and notable clearance of corneal findings.
The ongoing and emerging research surrounding LACRIFILL establishes it as a promising option for those suffering from dry eyes, a condition that affects millions worldwide. Nordic Pharma remains dedicated to expanding its portfolio and offering advanced therapeutic solutions. As the company progresses with its acquisitions and strategic development, it aims to enhance its foothold in the fields of ophthalmology, rheumatology, and women's health, leveraging its unique position within the global biopharmaceutical landscape. The company invites healthcare providers and patients to explore further details and ordering options for LACRIFILL Canalicular Gel via their website at lacrifill.com.
For further inquiries, Nordic Pharma can be contacted via Kate Popova, Project and Contract Manager, or Gail Feerrar, Director of Sales and Marketing, whose contact information is available in the press release. Nordic Pharma's commitment to enhancing patient care and driving innovation in eye health signifies a progressive pathway for addressing the challenges posed by dry eye syndrome and related ocular conditions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.